

**AUDITED FINANCIAL
STATEMENT**

FOR THE ACCOUNTING YEAR

2020-2021

OF

**SAROJA PHARMA INDUSTRIES INDIA
PRIVATE LIMITED**

By Auditors:
N H VARIAVA & CO
Chartered Accountant

B 13, Mahavir Kunj, Ambadi Road, Vasai Road West- 401202

Contact details

CA Niraj Variava,
Email: nirajvariava@gmail.com
Mobile No. 9960571408



**N H VARIAVA
& Co.**

Chartered Accountants

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF SAROJA PHARMA INDUSTRIES INDIA PRIVATE LIMITED

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying standalone financial statements of **Saroja Pharma Industries India Private Limited** ("the Company"), which comprise the Balance Sheet as at March 31, 2021, the Statement of Profit and Loss and statement of cash flow for the year ended on that date, and a summary of the significant accounting policies and other explanatory information. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2021 and its profit / (loss) and statement of cash flow for the year ended on that date.

Basis for Opinion


We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Emphasis of Matters

Attention is drawn to Note 31 of Financial Statements which describes the impacts of COVID-19 Pandemic on the financial statements as also on business operations of the Company, assessment thereof by the management of the Company based on its internal, external and macro factors, involving certain estimation uncertainties. Our opinion is not modified in respect of this matter

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134 (5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and statement of cash flow of the Company in accordance with the AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the



P

preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the Annexure a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, based on our audit we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss, statement of cash flow including Statement of Changes in Equity dealt with by this Report are in agreement with the relevant books of account.
 - d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of the written representations received from the directors as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) Since the Company's turnover as per last audited financial statements is less than Rs.50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs.25 Crores, the Company is exempted from getting an audit opinion with respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls vide notification dated June 13, 2017;
 - g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations, if any on its financial position in its standalone financial statements.
 - ii. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts.
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

For N H VARIAVA & CO.

Chartered Accountants

Firm's registration number: 153265W

Niraj Variava

Proprietor

Membership number: 146176

Place: Mumbai

Date : 03/09/2021

UDIN: 21146176AAAADK3121



ANNEXURE – A Report under the Companies (Auditor's Report) Order, 2016

(Referred to in paragraph 1 under 'Report on other legal and regulatory requirements' section of our report to the members of **Saroja Pharma Industries India Private Limited** of even date)

In terms of the information and explanations sought by us and given by the company and the books and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that: -

- (1) (a) The company has maintained records showing particulars of fixed assets but such records does not include quantitative details and situation of fixed assets.
- (1) (b) The Company has a program of verification to cover all the items of fixed assets in a phased manner over a period of once in a year, which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets.

Pursuant to the program, certain fixed assets were physically verified by the management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

- (1) (c) According to the information and explanations given to us, the records examined by us and based on the examination of the company do not have immovable property in name of company as on 31/03/2021.
- (2) As explained to us, the inventory has been physically verified at reasonable intervals during the year by the management. In our opinion, the frequency of verification is reasonable. The discrepancies noticed on verification between the physical stocks and the book records were not material. The discrepancies have been properly dealt with in the books of accounts
- (3) As explained to us, the company had not granted any loans, secured or unsecured, to any companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under section 189 of the Act. Accordingly, paragraph 3 (iii) of the order is not applicable.
- (4) In our opinion and according to information and explanation given to us, the company has not granted any loans or provided any guarantees or given any security or made any investments to which the provision of section 185 and 186 of the Companies Act, 2013. Accordingly, paragraph 3 (iv) of the order is not applicable.
- (5) In our opinion and according to the information and explanations given to us, the company has not accepted any deposits and accordingly paragraph 3 (v) of the order is not applicable.
- (6) The Central Government of India has not prescribed the maintenance of cost records under sub-section (1) of section 148 of the Act for any of the activities of the company and accordingly paragraph 3 (vi) of the order is not applicable.
- (7) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/ accrued in the books of account in respect of undisputed statutory dues including provident fund, employees' state insurance, income-tax, sales- tax, service tax, goods and service tax, duty of customs, duty of excise, value added tax, cess and other material statutory dues have been generally regularly deposited during the year by the company with the appropriate authorities.



SAROJA PHARMA INDUSTRIES INDIA PVT. LTD

CIN - U24110MH2019PTC319508

BALANCE SHEET AS AT 31st MARCH, 2021

	NOTES	31ST MARCH, 2021 Amount (Rs.)	31ST MARCH, 2020 Amount (Rs.)
<u>EQUITY & LIABILITIES:</u>			
<u>SHAREHOLDERS' FUNDS</u>			
Share Capital	2	1,00,000	1,00,000
Reserves and Surplus	3	92,59,383	19,46,348
<u>NON CURRENT LIABILITIES</u>			
Deferred Tax Liability		17,918	
<u>CURRENT LIABILITIES</u>			
Short Term Borrowings	4	3,01,76,513	1,71,74,337
Trade Payables	5	4,15,02,443	2,75,34,684
Other Current Liabilities	6	2,72,436	11,52,591
Short Term Provisions	7	9,10,351	2,79,594
TOTAL		8,22,39,044	4,81,87,554
<u>ASSETS:</u>			
<u>NON CURRENT ASSETS</u>			
Fixed Assets	8		
i) Tangible Assets		8,30,500	5,09,226
ii) Intangible Assets		44,488	44,998
Deferred Tax Assets	9		27,233
Long Term Investment	10	25,000	25,000
<u>CURRENT ASSETS</u>			
Inventories	11	65,61,000	26,68,740
Trade receivables	12	7,22,35,134	4,26,07,368
Cash and Cash Equivalents	13	41,292	7,53,043
Short-Term Loans and Advances	14	5,02,157	10,50,000
Other current assets	15	19,99,473	5,01,946
TOTAL		8,22,39,044	4,81,87,554

Notes Forming Part of Financial Statements

1-33

As per our report of even date

For N H Variava & Co**For and on behalf of the Board of Directors**

Chartered Accountants

(Firm Registration No.153265W)

**Niraj Variava**

Proprietor

Membership No. 146176

Place : Mumbai

Date : 03-09-2021

UDIN: 21146176AAAADK3121

**DIRECTOR**

BIJU NAIR

DIN -08330223

**DIRECTOR**

MANISH KAMBLE

DIN-08330224

SAROJA PHARMA INDUSTRIES INDIA PVT. LTD

CIN - U24110MH2019PTC319508

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH 2021

	NOTES	31ST MARCH, 2021 Amount (Rs.)	31ST MARCH, 2020 Amount (Rs.)
INCOME			
Revenue from operations	16	36,66,15,381	17,07,99,721
Other Income	17	8,51,460	60,335
Total Income (I)		36,74,66,841	17,08,60,056
EXPENSES			
Purchases		32,40,74,819	14,64,33,222
Direct Expenses	18	1,32,29,862	79,92,612
Changes in Inventories	19	(38,92,260)	(6,28,340)
Employee Benefit Expenses	20	84,88,848	60,81,496
Finance Costs	21	29,01,414	15,93,140
Depreciation	8	2,23,603	45,879
Other Expenses	22	1,20,85,941	71,91,092
Total Expenses (II)		35,71,12,227	16,87,09,101
Profit for the year before Tax	(I - II)	1,03,54,614	21,50,955
Tax Expenses :			
Current Tax		29,96,428	5,58,930
Deferred Tax		(45,151)	17,293
Profit/(Loss) for the period		73,13,035	16,09,318
Earning per equity share:			
Basic		731.30	160.93
Diluted		731.30	160.93

Notes Forming Part of Financial Statements

1-33


As per our report of even date

For N H Variava & Co

For and on behalf of the Board of Directors

Chartered Accountants

(Firm Registration No.153265W)



Niraj Variava
Proprietor
Membership No. 146176
Place : Mumbai
Date : 03-09-2021

UDIN: 21146176AAAADK3121



DIRECTOR
BIJU NAIR
DIN -08330223



DIRECTOR
MANISH KAMBLE
DIN-08330224

SAROJA PHARMA INDUSTRIES INDIA PVT. LTD

CIN - U24110MH2019PTC319508

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2021

PARTICULARS	YEAR ENDED MARCH 31, 2021	YEAR ENDED MARCH 31, 2020
A) CASH FLOW OPERATING ACTIVITIES		
Net Profit before Tax		
Adjustments :	1,03,54,614	21,50,955
Prior period item	-	-
Depreciation & amortisation expenses	2,23,603	-
Finance Charges Paid	29,01,414	45,879
	31,25,017	15,93,140
Less : Interest received	1,34,79,631	16,39,019
Dividend	40,574	37,89,974
Profit/(loss) on sale of Asset	-	-
Profit on sale of Investment	-	-
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	40,574	13,942
	1,34,39,057	37,76,032
Adjustment for :-		
(Increase)/ decrease Trade receivables	(2,96,27,766)	(2,88,81,288)
(Increase)/decrease in other financial assets, other non-current and current assets	(14,97,527)	3,67,185
(Increase)/ decrease Inventory	(38,92,260)	(6,28,340)
Increase/ (decrease) Trade payable	1,39,67,759	1,60,13,765
Increase/(decrease) in other financial liabilities, provisions and other current and non-current liabilities	(2,49,398)	10,47,515
	(2,12,99,192)	(1,20,81,163)
NET CASH FLOW FROM OPERATING ACTIVITIES	(78,60,135)	(83,05,131)
Less : Taxes paid	(29,96,428)	(5,58,930)
NET CASH FLOW FROM OPERATING ACTIVITIES	(1,08,56,563)	(88,64,061)
B) CASH FLOW FROM INVESTMENT ACTIVITIES:-		
Purchase of fixed assets (net of sales)	(5,44,367)	(2,27,037)
Interest Received	40,574	13,942
Purchase of Shares	-	(25,000)
Dividend	-	-
Purchase of fixed assets (net of sales)	-	-
NET CASH USED IN INVESTING ACTIVITIES	(5,03,793)	(2,38,095)
C) CASH FLOW FROM FINANCE ACTIVITIES		
Issue of shares	-	-
Finance Charges Paid	(29,01,414)	(15,93,140)
Short Term Advance given	5,47,843	(10,50,000)
Increase/ (decrease) Borrowings (current and non current)	1,30,02,176	1,23,59,026
NET CASH FLOW FROM FINANCE ACTIVITIES	1,06,48,605	97,15,886
NET (DECREASE)INCREASE IN CASH & CASH EQUIVALENTS (A+B+C)	(7,11,751)	6,13,730
Opening Balance of Cash & cash equivalents	7,53,043	1,39,313
Closing Balance of Cash & cash equivalents	41,292	7,53,043

* The previous year figures have been regrouped/restated where ever necessary to confirm to this year's classification
 * The cash flow statement has been prepared under the indirect method

For N H Variava & Co

For and on behalf of the Board of Directors

Chartered Accountants
(Firm Registration No.153265W)

Niraj Variava
Proprietor
Membership No. 146176
Place : Mumbai
Date : 03-09-2021
UDIN: 21146176AAAADK3121



Biju Nair
Manish Kamble

DIRECTOR
BIJU NAIR
DIN - 08330223

DIRECTOR
MANISH KAMBLE
DIN - 08330224

SAROJA PHARMA INDUSTRIES INDIA PVT. LTD
CIN - U24110MH2019PTC319508
NOTES FORMING PART OF THE FINANCIAL STATEMENT AS AT 31ST MARCH, 2021

	PARTICULARS			31ST MARCH, 2021	31ST MARCH, 2020
2	<p>Share Capital</p> <p>Authorised 10,000 Equity Shares of Rs. 10/- each</p> <p>Total Authorised Share Capital</p> <p>Issued, Subscribed and Paid up 10,000 Equity Shares of Rs. 10/- each</p> <p>Total Issued, Subscribed And Fully Paid Up Share Capital</p>			1,00,000 1,00,000 1,00,000 1,00,000	1,00,000 1,00,000 1,00,000 1,00,000
a. Reconciliation of shares outstanding at the beginning and at the end of the reporting period					
Equity shares of Rs. 10 each					
		31st March, 2021		31st March, 2020	
		Numbers	Rs.	Numbers	Rs.
At the beginning of the period		10,000	1,00,000	10,000	1,00,000
Issued during the period		-	-		
Bought back during the period		-	-		
Outstanding at the end of the period		10,000	1,00,000	10,000	1,00,000
b. Terms/rights attached to equity shares					
<p>The Company has only one class of Equity Shares having par value of Rs. 10. Each holder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.</p> <p>In the event of liquidation of the Company, the holder of equity shares will be entitled to receive any of the remaining assets of the company, after distribution of all preferential amount. The distribution will be in proportion to the number of equity shares held by the shareholders.</p>					
C. Details of shareholders holding more than 5% shares in the company					
		31st March, 2021		31st March, 2020	
		Numbers	% of holding	Numbers	% of holding
BIJU GOPINATH NAIR		7,000	70	7,000	70
MANISH DASHARATH KAMBLE		3,000	30	3,000	30
Total		10,000	100	10,000	100
3	<p>Reserve & Surplus</p> <p>Surplus/(Deficit) in the Statement of Profit and Loss</p> <p>Balance as per last financial statements</p> <p>Profit/ (loss) for the year</p> <p>Closing balance</p> <p>Total Reserves and Surplus</p>			19,46,348 73,13,035 92,59,383 92,59,383	3,37,030 16,09,318 19,46,348 19,46,348
4	<p>Short Term Borrowings</p> <p>Secured Loan Repayable on Demand</p> <p>Bank overdraft with Saraswat Bank</p> <p>CC with Saraswat Bank Ltd</p> <p>Unsecured Loan Repayable on Demand</p> <p>From Directors</p> <p>Total Short Term Borrowings</p> <p>Note:</p> <p>1) Loan secured against the property of Director. 2) Guarantee by Directors.</p>			(12,09,994) 1,72,24,915 1,41,61,592 3,01,76,513	1,20,49,337 51,25,000 1,71,74,337
5	<p>Trade payable</p> <p>Trade Payable for Goods Purchased</p> <p>Trade Payable for Services Received</p> <p>Total</p>			3,97,71,164 17,31,279 4,15,02,443	2,55,07,398 20,27,286 2,75,34,684



SAROJA PHARMA INDUSTRIES INDIA PVT. LTD
CIN - U24110MH2019PTC319508
NOTES FORMING PART OF THE FINANCIAL STATEMENT AS AT 31ST MARCH, 2021

PARTICULARS		31ST MARCH, 2021	31ST MARCH, 2020
6	Other Current Liabilities		
	TDS payable		4,18,029
	GST Payable	2,46,534	7,32,362
	TCS payable	25,902	-
	Professional Tax Payable	-	2,200
	Total	2,72,436	11,52,591
7	Short Term Provisions		
	Provision for expenses	1,53,441	1,81,774
	Provision for income tax	7,56,910	97,820
	Total	9,10,351	2,79,594
9	Deferred Tax Assets (Net)		
	For Depreciation	-	27,233
	Total	-	27,233
10	Long Term Investment		
	Unquoted Equity Shares		
	2500 Equity Shares of Saraswat Co-op Bank Ltd	25,000	25,000
	Total	25,000	25,000
11	Inventories		
	<i>(Certified and Valued by management)</i>		
	Closing stock	65,61,000	26,68,740
	Total	65,61,000	26,68,740
12	Trade receivables		
	<i>(Unsecured, Considered Good)</i>		
	Over Six Months		
	Others	7,22,35,134	4,26,07,368
	Total	7,22,35,134	4,26,07,368
13	Cash and Cash Equivalents		
	(i) Cash and Cash Equivalents		
	Cash on hand	20,272	26,051
	Balance with bank	10,864	13,050
	(ii) Other Bank Balances		
	Recurrine Deposit at Bank	10,157	7,13,942
	Total Cash And Cash Equivalents	41,292	7,53,043
14	Short-Term Loans and Advances		
	Advance to Trade Payable/ Creditors	-	10,50,000
	Loan to staff	5,02,157	-
	Total	5,02,157	10,50,000
15	Other Current Assets		
	Deposits	3,05,600	2,03,100
	GST Refund	35,632	70,632
	GST Credit balance	13,66,097	-
	Duty Drawback receivable	94,250	-
	TCS on Purchase Receivables	14,220	-
	Prepaid Expenses	1,83,674	2,28,214
	Total Other Current Assets	19,99,473	5,01,946



(Handwritten signature)

SAROJA PHARMA INDUSTRIES INDIA PVT. LTD
CIN - U24110MH2019PTC319508

NOTES FORMING PART OF THE FINANCIAL STATEMENT AS AT 31ST MARCH, 2021

	PARTICULARS	31ST MARCH, 2021	31ST MARCH, 2020
16	<u>Revenue From Operations</u>		
	Sales	36,66,15,381	17,07,99,721
	Total Revenue from Operations	36,66,15,381	17,07,99,721
17	<u>Other Income</u>		
	Interest on Recurring Deposit	40,574	13,942
	Gain on Foreign Exchange (Net)	1,14,673	46,393
	Duty Draw Back Income	6,96,213	-
	Total Revenue from Operations	8,51,460	60,335
18	<u>Direct Expenses</u>		
	Transportation Charges	1,11,45,455	79,78,953
	Detention Charges	30,000	-
	Loading/Unloading Charges	1,56,650	-
	Export Expenses	18,97,757	13,659
	Total	1,32,29,862	79,92,612
19	<u>Changes in Inventories</u>		
	(Valued and certify by management)		
	Opening Stock	26,68,740	20,40,400
	Less : Closing Stock	(65,61,000)	(26,68,740)
	Total	(38,92,260)	(6,28,340)
20	<u>Employee Benefit Expenses</u>		
	Salary	48,28,500	21,47,600
	Director Remuneration	31,20,000	38,70,000
	Bonus Paid	4,29,500	1,98,500
	Staff Welfare	1,10,848	63,896
	Total	84,88,848	60,81,496
21	<u>Financial Cost</u>		
	Interest on Over Draft	3,00,980	9,49,157
	Interest on CC	14,45,621	-
	Interest Paid on Loan	8,79,236	5,07,093
	Bank Charges	2,75,577	1,36,890
	Total	29,01,414	15,93,140



SAROJA PHARMA INDUSTRIES INDIA PVT. LTD
CIN - U24110MH2019PTC319508

NOTES FORMING PART OF THE FINANCIAL STATEMENT AS AT 31ST MARCH, 2021

	PARTICULARS	31ST MARCH, 2021	31ST MARCH, 2020
22	Other Expenses		
	Audit Fees	40,000	25,000
	Advertisement & PR Expenses	-	5,00,000
	Business Promotion Expenses	10,34,162	5,75,470
	Commission Expenses	81,67,259	45,19,564
	Computer Expenses	31,702	20,113
	Conveyance Charges	3,04,010	28,000
	Courier Charges	75,827	60,183
	Discount	20,011	-
	Diwali Expenses	1,84,426	1,77,658
	Donation	5,000	-
	Electricity Expenses	26,120	24,200
	Foreign Conversion & Bank Charges	3,93,449	-
	Godown Cleaning Charges	-	9,500
	Insurance Charges	2,92,519	93,065
	Interest on TDS late payment	24,084	-
	Laboratories Expenses	-	4,770
	Legal Charges	28,000	87,130
	Office Expenses	1,35,990	99,580
	Office Rent	4,63,500	3,61,500
	Printing & Stationery	79,822	23,302
	Professional Fees	94,518	54,838
	Profession Tax - Company	5,000	2,500
	Tea & Refreshment Expenses	67,067	80,401
	Telephone Expenses	89,949	52,886
	Amount W/off	6,703	-
	Travelling Expenses	5,16,823	1,92,932
	Total Other Expenses	1,20,85,941	71,91,092



R

Name: SAROJA PHARMA INDUSTRIES INDIA PVT. LTD.

A. Y. 2021-2022

Schedule 7

Depreciation as per Income Tax Act

Block	Rate	WDV as on 01-Apr- 2020	Additions (put to use) up to 03- Oct-2020	Additions (put to use) after 03-Oct- 2020	Deletions	Total	Depreciation	WDV as on 31-Mar- 2021
4. Furnitures/ fittings 10%:	10%	1,71,677		42,000		2,13,677	19,268	1,94,409
5. Plant/ Machinery 15%: not covered in other blocks, cars...	15%	1,17,238	3,07,512	60,585		4,85,335	68,256	4,17,079
7. Plant/ Machinery 40%: computer, energy saving devices...	40%	1,21,128	80,253	36,017		2,37,398	87,756	1,49,642
10. Intangible assets 25%:	25%	35,250		18,000		53,250	11,063	42,187
Total		4,45,293	3,87,765	1,56,602		9,89,660	1,86,343	8,03,317



[SAROJA PHARMA INDUSTRIES INDIA PVT. LTD.]

SAROJA PHARMA INDUSTRIES INDIA PVT. LTD

CIN - U24110MH2019PTC319508

FINANCIAL YEAR - 2020-21

NOTE 8 : FIXED ASSETS

Particulars	Gross Block				Depreciation				Net Block
	As at April 1, 2020	Additions	Deductions	As at March 31, 2021	As at April 1, 2020	For the year	Deductions	As at March 31, 2021	As at March 31, 2021
Tangible Assets									
Computer	2,22,699	1,16,269.86	-	3,38,969	26,490	91,305.74		1,17,796	2,21,173
Furniture & Fixtures	1,75,000	42,000.00		2,17,000	7,485	17,608.84		25,094	1,91,906
Mobile Phone	25,875	3,50,724.64		3,76,599	6,025	71,972.74		77,998	2,98,601
Motor Vehicle	66,676			66,676	1,012	6,334.22		7,346	59,330
Office Equipment	32,872	17,372.88		50,245	2,684	6,990.07		9,674	40,571
camera	34,362			34,362	4,561	10,881		15,443	18,919
Total	5,57,483	5,26,367	-	10,83,851	48,258	2,05,093	-	2,53,351	8,30,500
Intangible Assets									
Software	51,500	18,000	-	69,500	6,502	18,510	-	25,012	44,488
Grand Total	6,08,983	5,44,367		11,53,351	54,759	2,23,603		2,78,362	8,74,988
Previous Year	3,81,946	2,27,037		6,08,983	8,880	45,879		54,759	5,54,224



M/S SAROJA PHARMA INDUSTRIES INDIA PVT. LTD

NOTES FORMING PART OF FINANCIAL STATEMENT AS AT 31ST MARCH, 2021

1. SIGNIFICANT ACCOUNTING POLICES :

(a) Basis of Preparation of Financial Statements

The financial statements are prepared in accordance with Generally Accepted Accounting Principles ("GAAP") in India under the historical cost convention, on accrual basis of accounting and comply with Accounting Standard notified under section 133 of Companies Act, 2013 read with Rule 7 of Companies (Accounts) Rules, 2014. The accounting policies have been consistently applied by the Company and are consistent with those used in the previous year.

(b) Going Concern Assumption:-

The financial statements have been prepared assuming entity will be able to continue its operation in near foreseeable future and there is no material circumstances casting doubt over going concern ability of company and neither management intends to liquidate its operations.

(c) Inventory valuation

Items of inventories are measured at lower of cost and net realizable value after providing for obsolescence, if any. Cost of inventories comprises of cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost of inventories is determined on First-in-First-Out (FIFO) basis.

(d) Use of Estimates

The Preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Any revision to the accounting estimates is recognized prospectively.

(e) Revenue recognition

Revenue is recognized when it is earned and no significant uncertainty exists as to its ultimate realization or collection.

Other Income is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.



A handwritten signature or initials in blue ink, located to the right of the stamp.

(f) Property, Plant & Equipment

Tangible Assets

Fixed assets are stated at cost, less accumulated depreciation and impairment losses if any. Cost comprises the purchase price and any attributable cost of bringing the asset to its working condition for its intended use. Borrowing costs relating to acquisition of fixed assets which takes substantial period of time to get ready for its intended use are also included to the extent they relate to the period till such assets are ready to be put to use. Capital work in progress includes expenditure incurred till the assets are put into intended use.

Intangible Assets

Intangible Assets are stated at cost of acquisition net of recoverable taxes less accumulated amortisation / depletion and impairment loss, if any. The cost comprises purchase price, borrowing costs, and any cost directly attributable to bringing the asset to its working condition for the intended use and net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the intangible assets.

(g) Depreciation

Depreciation on tangible assets is provided using the Straight Line Method over the useful lives of the assets estimated by the Management. Depreciation for the assets purchased / sold during the year is proportionately charged as prescribed in Schedule II to the Companies Act, 2013. Intangible assets are amortised over their respective individual estimated useful lives on a straight line basis, commencing from the date the asset is available to the Company for its use.

(h) Impairment of assets

The carrying amounts of assets are reviewed at each balance sheet dates and if there is any indication of impairment based on internal/external factors. An impairment loss is recognized wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the greater of the asset's net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value at the weighted average cost of capital. If at the balance sheet date, there is an indication that a previously assessed impairment loss no longer exists, then such loss is reversed and the asset is restated to extent of the carrying value of the asset that would have been determined (net of amortization / depreciation), had no impairment loss been recognized.

After impairment, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

(i) Investments

Investments that are readily realizable and intended to be held for not more than one year are classified as current investments. All other investments are classified as long-term investments. Current investments are carried at lower of cost or fair value determined on individual investment basis. Long-term investments are carried at cost. However, provision



(Handwritten signature)

for diminution in value is made to recognize a decline other than temporary decline in the value of the investments.

(j) Taxation

Tax expense comprises of current and deferred. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with the Indian Income Tax Act. Deferred income taxes reflects the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years.

Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

At each balance sheet date the Company re-assesses unrecognized deferred tax assets. It recognizes unrecognized deferred tax assets to the extent that it has become reasonably certain or virtually certain, as the case may be that sufficient future taxable income will be available against which such deferred tax assets can be realized.

The carrying amount of deferred tax assets are reviewed at each balance sheet date. The company writes-down the carrying amount of a deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available

(k) Provision, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognized when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. Contingent Liabilities are not recognized but are disclosed in the Notes. Contingent Assets are neither recognized nor disclosed in the financial statements.

(l) Earnings per Share

The Company reports basic and diluted earnings per share in accordance with AS-20 "Earnings per Share". Basic earnings per share are computed by dividing the net profit or loss for the period by the weighted average number of Equity Shares outstanding during the period. Diluted earnings per share is computed by dividing the net profit or loss for the period by the weighted average number of Equity Shares outstanding during the period as adjusted for the effects of all dilutive potential equity shares.



M/S SAROJA PHARMA INDUSTRIES INDIA PVT. LTD

NOTES FORMING PART OF FINANCIAL STATEMENT AS AT 31ST MARCH, 2020

23. Contingent Liabilities not provided for:

Particulars	<u>2020-21</u> <u>Amount in Rs.</u>	<u>2019-20</u> <u>Amount in Rs.</u>
Claims against the company not acknowledged as debts	NIL	NIL
Others	NIL	NIL

24. Earning Per Share:

Particulars	<u>2020-21</u> <u>Amount in Rs.</u>	<u>2019-20</u> <u>Amount in Rs.</u>
Net profit/(loss) for the year attributable to equity shareholders (Rs.)	73,13,035	16,09,318
Weighted Average No. of Equity shares outstanding for Basic Earning per share	10,000	10,000
Weighted Average No. of Equity shares outstanding for Diluted earning per share	10,000	10,000
Basic Earning per share (face valued of Rs 10/- each) (Rs.)	731.30	160.09
Diluted earning per share (face valued of Rs 10/- each) (Rs.)	731.30	160.09

25. Related Party Disclosures :

➤ **Key Management Personnel**

BIJU GOPINATH NAIR
MANISH DASHARATH KAMBLE



➤ **Transactions with Related Parties**

Name of Related Party	Nature of Transaction	<u>2020-21</u> <u>Amount in Rs.</u>	<u>2019-20</u> <u>Amount in Rs.</u>
BIJU GOPINATH NAIR	Balance at the beginning of the year	40,00,000	48,15,311
	Loan Taken	93,44,000	2,15,389
	Loan Repaid	8,82,408	10,37,700
	Balance at the end of the year	1,24,61,592	40,00,000
	Remuneration	19,20,000	25,20,000
MANISH DASHARATH KAMBLE	Balance at the beginning of the year	11,25,000	NIL
	Loan Taken	43,75,000	50,85,000
	Loan Repaid	38,00,000	39,60,000
	Balance at the end of the year	17,00,000	11,25,000
	Remuneration	12,00,000	13,50,000

26. Foreign Exchange Earning and Expense :

Particulars	<u>2020-21</u> <u>Amount in Rs.</u>	<u>2019-20</u> <u>Amount in Rs.</u>
Foreign Exchange earning	5,41,52,453	6,48,000
Foreign Exchange Expenses	14,13,044	44,48,290
Reimbursement of Expenditure in foreign currency	Nil	Nil

27. In the opinion of the Board & to the best of their knowledge & belief the value of realization of current assets, loans & advances in the ordinary course of business would not be less than the amount at which they are stated in the Balance Sheet & the provisions for all the loans & determined liabilities is adequate and not in excess of the amount.

28. Segment Information: The Company is engaged in single segment and there are no separate reportable segments as defined in AS-17

29. Trade Receivable, Trade Payable, Short Term Borrowings and Short Term Loans and Advances balances are subject to confirmation and reconciliation.



30. As per information available with the Company, none of the creditors has confirmed that they are registered under the Micro, Small and Medium enterprises Development Act, 2006.
31. The Company has considered the possible impact that may arise from CoVID-19, a global pandemic, on the carrying amount of its assets including Property, Plant and Equipment, Inventory and Receivables. In developing the assumptions relating to the impact of possible future uncertainties in global economic conditions because of this pandemic, the Company as at the date of approval of these financial statement has used internal and external sources of information including economic forecasts.

The Company based on current estimates expects that the carrying amount of the above assets will be recovered, net of provisions established. The Company has also assessed the impact of this whole situation on its Capital and Financial Resources, Profitability, Liquidity Position, Internal Financial Controls, etc. and is of the view that based on its present assessment, this situation does not materially impact these financial statement. The impact assessment does not indicate any adverse impact on the ability of the Company to continue as a going concern. However, the impact assessment of CoVID-19 is a continuing process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions.

Considering the Company's nature of business, management does not anticipate any serious challenges/ significant impact on continuity of its business.

32. Balances of Loans and Advances and Unsecured Loans are subject to confirmation and reconciliation and consequential adjustments, if any.
33. Balances of Debtors, Loans and Advances, Secured Loans, Sundry Creditors & Others are subject to confirmation and reconciliation and consequential adjustments, if any.

As Per Our Report of Even Date

For N H VARIAVA & CO
Chartered Accountants

Niraj Variava
Proprietor
M.No. 146176

Place: Mumbai

Date: 03/09/2021

UDIN: 21146176A AADK3121



For And On Behalf Of the Board Of

M/s SAROJA PHARMA INDUSTRIES INDIA PVT. LTD

BIJU NAIR
(Director)

DIN -08330223

MANISH KAMBLE
(Director)

DIN-08330224